🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

DEA will formally oppose or delay any pending ibogaine rescheduling petition before December 31, 2026, citing cardiovascular adverse event literature published in 2026.

Predicted 2026-05-09 · Resolves 2026-12-31 · regulation · USA
41%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

If someone files an official petition to move ibogaine from Schedule I (banned) to a looser category, the DEA (US drug enforcement agency) will reject it by citing the new heart safety papers published in 2026. This prediction only matters if a petition actually gets filed first — as of now, none is publicly confirmed.

This prediction is only falsifiable if a rescheduling petition is actually pending or filed before the resolve date — otherwise DEA has nothing to formally oppose. As of May 2026 no such petition is publicly confirmed. The prediction is conditionally probable (DEA institutional posture strongly favors delay) but contingent on the triggering condition. Confidence reduced substantially from single-agent raw score to reflect the conditional dependency and the absence of a confirmed petition.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →